[A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer].
A 69-year-old patient with advanced stomach cancer (Borrmann III) was treated with a combination chemotherapy regimen of cis-platinum administered one week after a course of PSK and FT-207. The maximum dosage of CDDP administered was gradually increased step by step from 20 mg/day to 40 mg/day every week. A remarkable decrease of tumor size was observed upon stomach x-ray and endoscopical examination. The cancer marker, serum CEA, determined by RIA also decreased from 59 ng/ml to 3.5 ng/ml. Moreover, no gastrointestinal disturbance was observed during this trial. From the results experienced, in this case, the combination therapy of PSK and FT-207 with CDDP was considered to be one of the most effective antineoplastic therapies available for stomach cancer, suppressing the gastrointestinal disturbances which are usually induced by CDDP administration alone.
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D011509:Proteoglycans / Q000008:administration & dosage; D011859:Radiography; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage
D011509:Proteoglycans; D005641:Tegafur; C010770:polysaccharide-K; D002945:Cisplatin